Common ED Drug Linked to Retina Risk
New study suggests sildenafil may slightly increase the risk of serous retinal detachment, though absolute risk remains very low
A large observational study suggests that men with erectile dysfunction who use sildenafil may have a higher relative risk of developing serous retinal detachment. However, the overall risk remains rare, affecting fewer than 1 in 2,000 users over a one-year period.
Study Details
Sildenafil is one of the most widely prescribed treatments for erectile dysfunction and works by inhibiting phosphodiesterase type 5 (PDE5), which improves blood flow. Because PDE5 inhibitors also affect vascular pathways throughout the body, researchers have long investigated whether these drugs might influence eye circulation.
Previous signals from insurance claims databases suggested a possible link between PDE5 inhibitors and certain retinal disorders. The new study sought to examine this association more rigorously using a large electronic health record database covering more than 70 healthcare systems in the United States.
Researchers focused specifically on serous retinal detachment, a condition in which fluid accumulates under the retina and separates it from underlying tissue. This can lead to blurred or distorted vision if not treated promptly.
Methodology
Researchers conducted a retrospective cohort study using electronic health records from more than 70 US health systems. Adult men diagnosed with erectile dysfunction were identified and divided into two groups based on sildenafil use. To minimize bias, investigators used propensity score matching to pair sildenafil users with nonusers who had similar health profiles. This produced two comparable groups of 208,930 patients each, with average ages of about 57 years. Participants were followed for one year to assess the incidence of serous retinal detachment as the primary outcome. Secondary outcomes included retinal vascular occlusion and ischemic optic neuropathy.
Key Findings
Sildenafil users had a 54% higher relative risk of serous retinal detachment compared with nonusers.
The absolute risk remained very low:
0.04% in sildenafil users
0.02% in nonusers
No increased risk was observed for retinal vascular occlusion.
No increased risk was observed for ischemic optic neuropathy.
Implications for Practice
For most patients, these findings are unlikely to change clinical practice because the absolute risk is extremely small. Sildenafil remains a widely used and effective therapy for erectile dysfunction with a strong safety record.
However, the results may be relevant for specific groups of patients, particularly those with existing retinal disease or a history of retinal detachment. Clinicians may wish to discuss visual symptoms with patients using PDE5 inhibitors and advise them to seek prompt evaluation if they experience sudden visual distortion, flashes, or blurred vision.
From a biological perspective, the association could reflect sildenafil’s effects on choroidal blood flow and vascular permeability in the eye. PDE5 inhibition may influence fluid dynamics in the retina, which could theoretically contribute to fluid accumulation in susceptible individuals.
Future studies may help determine whether the effect is limited to certain patients or specific dosing patterns.